184944-86-3

Usage

Molecular structure

A complex compound containing a benzodiazepine core, an amino group, dioxo and phenyl groups, and isopropyl and phenylacetamide side chains.

Classification

Derivative of benzodiazepine, a class of psychoactive drugs.

Psychoactive properties

Known for their sedative and anxiolytic (anti-anxiety) effects.

Functional groups

Presence of an amino group, dioxo, phenyl groups, and side chains such as isopropyl and phenylacetamide.

Potential pharmaceutical properties

May act as a central nervous system depressant due to the presence of functional groups.

Further research needed

To determine the specific effects and potential uses of the compound.

Upstream product

• 534-85-0 N-phenyl-1,2-benzenediamine 
• 161455-90-9 N-isopropyl-N-phenyl-2-(2-phenylamino-phenylamino)-acetamide 
• 161455-97-6 2-bromo-N-isopropyl-N-phenyl-acetamide 
• 161455-91-0 2-[2,4-Dioxo-5-phenyl-3-(phenyl-hydrazono)-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl]-N-isopropyl-N-phenyl-acetamide 

Downstream Products

• 184944-89-6 [3-(3-{1-[(Isopropyl-phenyl-carbamoyl)-methyl]-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl}-ureido)-phenoxy]-acetic acid tert-butyl ester 
• 184945-28-6 N-Isopropyl-2-{3-[3-(3-nitro-phenyl)-ureido]-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl}-N-phenyl-acetamide 
• 184945-07-1 N-Isopropyl-2-{3-[3-(3-methylsulfanyl-phenyl)-ureido]-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl}-N-phenyl-acetamide 

Relevant academic research and scientific papers

Use of 1,5-benzo?b!1,4-diazepines to control gastric emptying

A method of controlling gastric emptying in patients having an early non-insulin-dependent diabetic condition and exhibiting rapid gastric emptying comprising the administration of an effective gastric emptying controlling amount of a compound of Formula

Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amino substituent

Analogs of the previously reported 1,5-benzodiazepine peripheral cholecystokinin (CCK-A) receptor agonist 1 were prepared which explore substitution and/or replacement of the C-3 phenyl urea moiety. Agonist efficacy on the isolated guinea pig gallbladder (GPGB) was retained with a variety of substituted ureas and amide analogs. Three compounds were identified which were orally active in the mouse gallbladder emptying assay (MGBE). The 2-indolamide (52) and N-(carboxymethyl)-2-indolamide (54) derivatives had improved affinity for the human CCK-A receptor but reduced agonist efficacy on the GPGB. Neither indolamide was orally active in a rat feeding assay. In contrast, the (3-carboxyphenyl)urea derivative (29, GW7854) had moderately increased affinity for the human CCK-B receptor but was a potent full agonist on the GPGB and was orally active in both the MGBE and rat feeding assays. GW7854 was a full agonist (EC50 = 60 nM) for calcium mobilization on CHO K1 cells expressing hCCK-A receptors and a potent antagonist of CCK-8 (pA2 = 9.1) on CHO K1 cells expressing hCCK-B receptors. GW7854 is a potent mixed CCK-A agonist/CCK-B antagonist which is orally active in two in vivo models of CCK-A-mediated agonist activity.

3-[2-(N-phenylacetamide)]-1,5-benzodiazepines: Orally active, binding selective CCK-A agonists

A series of modifications were made to the C-3 substituent of the 1,5- benzodiazepine CCK-A agonist 1. Replacement of the inner urea NH and addition of a methyl group to generate a C-3 quaternary carbon resulted in acetamide 6, which showed CCK-A receptor